Marker Therapeutics, Inc. · NASDAQ:MRKR
Marker Therapeutics — Investor Presentation (January 2024)
21 slides from Marker Therapeutics's investor presentation, Jan 8, 2024
Slide 1: Marker Therapeutics Corporate Presentation January 2024
MARKER THERAPEUTICS CORPORATE PRESENTATION January 2024
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements contained herein are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as am
Slide 3: Marker Therapeutics Overview
Marker Therapeutics Overview • Multi targeted T cell therapy • Does not require genetic engineering • Non-clinical proof-of-concept data Marker is a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignanc
Slide 4: Simple Manufacturing Process
Simple Manufacturing Process G-Rex® 500M Culture Initiation Expansion of multiTAA-specific T Cells Day 9 Cell Harvest multiTAA Product + Cytokines + Peptides Incubation without Interventions PBMCs(1) G-Rex’s unique gas permeable membrane allows for uninterrupted expansion A single G-Rex device can p
Slide 5: Marker's multiTAA-Specific T Cell Pipeline
Marker’s multiTAA-Specific T Cell Pipeline HEMATOLOGIC MALIGNANCIES MT-601 MT-601 MT-401-OTS INDICATION PRECLINICAL PHASE 1 PHASE 2 AML(1) Off-the-Shelf (OTS) Lymphoma Patient-specific PC(2) Patient-specific (1) AML, Acute Myeloid Leukemia (2) PC, Pancreatic Cancer IND SOLID TUMORS INDICATION PRECLI
Slide 6: Marker's multiTAA-Specific T Cell Pipeline
Marker’s multiTAA-Specific T Cell Pipeline (1) AML, Acute Myeloid Leukemia (2) PC, Pancreatic Cancer HEMATOLOGIC MALIGNANCIES MT-601 INDICATION PRECLINICAL PHASE 1 PHASE 2 Lymphoma Patient-specific IND 6
Slide 7: Durability of Response of multiTAA-Specific T Cells vs. CAR T Cells in Lymphoma
Durability of Response of multiTAA-Specific T Cells vs. CAR T Cells in Lymphoma Durability of Response multiTAA-specific Ts (6 years) vs CAR Ts (15 months) Potent and Specific multiTAA have shown potent and specific anti-tumor activity HL: Hodgkin’s Lymphoma; NHL: Non-Hodgkin’s Lymphoma Vasileiou S
Slide 8: Lymphoma Cells Become Resistant to CD19 CAR T Cells
• Hodgkin’s lymphoma cell line engineered to overexpress CD19. • Lymphoma cells relapse 3 weeks after initial anti-CD19 CAR T cell treatment. 0 5 10 15 20 25 0 20 40 60 Days in vitro Lymphoma Cell Growth Fold Change in Lymphoma Cell Growth Control Lymphoma anti-CD19 CAR T infused Lymphoma B CD19-neg
Slide 9: CD19 Antigen Escape Results in CAR Resistant Lymphoma Cells
• Hodgkin’s lymphoma cell line engineered to overexpress CD19. • Lymphoma cells relapse 3 weeks after initial anti-CD19 CAR T cell treatment. • Resistant lymphoma cells are negative for CD19. 0 5 10 15 20 25 0 20 40 60 Days in vitro Lymphoma Cell Growth Fold Change in Lymphoma Cell Growth Control Ly
Slide 10: Antigen-Negative Lymphoma Cells are CD19 CAR Refractory
Antigen-Negative Lymphoma Cells are CD19 CAR Refractory 0 5 10 15 20 25 0 20 40 60 Days in vitro Lymphoma Cell Growth Fold Change in Lymphoma Cell Growth Control Lymphoma anti-CD19 CAR T infused Lymphoma 0 5 10 0 20 40 60 80 100 Fold Change in Lymphoma Cell Growth Control Lymphoma anti-CD19 CAR T in
Slide 11: MT-601 Demonstrates Anti-Tumor Activity in CAR Refractory Lymphoma Cells
0 5 10 15 20 25 0 20 40 60 Days in vitro Lymphoma Cell Growth Fold Change in Lymphoma Cell Growth Control Lymphoma anti-CD19 CAR T infused Lymphoma 0 5 10 0 20 40 60 80 100 Fold Change in Lymphoma Cell Growth Control Lymphoma anti-CD19 CAR T infused Lymphoma CD19 Antigen FSC 98% 0.34% CD19 Antigen F
Slide 12: First Study Participant Treated with MT-601 in Phase 1 APOLLO Trial
First Study Participant Treated with MT-601 in Phase 1 APOLLO Trial Demographics • 57-year-old female • Diagnosed with DLBCL(1) Clinical History • 4 Prior treatment lines, including CD19 CAR T cells • Relapse within 90 days after CD19 CAR T cell therapy • Subsequent treatment with 2 doses of MT-601
Slide 13: Complete Response in Lymphoma Patient Treated with MT-601 after CAR T Relapse
Complete Response in Lymphoma Patient Treated with MT-601 after CAR T Relapse MT-601 Clinical Safety • MT-601 treatment was well tolerated • No > Grade 1 treatment-related adverse events Clinical Response • Study participant achieved complete metabolic response 8 weeks after 2nd infusion of MT-601 •
Slide 14: Clinical Investigation of MT-601 in Marker's APOLLO Trial
Clinical Investigation of MT-601 in Marker’s APOLLO Trial APOLLO Trial Investigate MT-601 in a Phase 1, multicenter, open-label study Study Participants Lymphoma patients who relapsed after or are ineligible for anti-CD19 CAR T cell therapy Primary Objective Evaluate safety and efficacy of MT-601 in
Slide 15: Future Developments
Future Developments
Slide 16: Marker's multiTAA-Specific T Cell Pipeline
Marker’s multiTAA-Specific T Cell Pipeline (1) AML, Acute Myeloid Leukemia (2) PC, Pancreatic Cancer HEMATOLOGIC MALIGNANCIES INDICATION PRECLINICAL IND PHASE 1 PHASE 2 MT-401-OTS AML(1) Off-the-Shelf (OTS) 16
Slide 17: Off-the-Shelf (OTS) Production and Treatment Strategy
Off-the-Shelf (OTS) Production and Treatment Strategy 2 GMP Facility 1 3 4 5 17
Slide 18: Marker's multiTAA-Specific T Cell Pipeline
Marker’s multiTAA-Specific T Cell Pipeline (1) AML, Acute Myeloid Leukemia (2) PC, Pancreatic Cancer MT-601 PC(2) Patient-specific SOLID TUMORS INDICATION PRECLINICAL IND PHASE 1 PHASE 2 18
Slide 19: MultiTAA-specific T cells Demonstrated Benefit to SOC Chemotherapy in Pancreatic Cancer
MultiTAA-specific T cells Demonstrated Benefit to SOC Chemotherapy in Patients with Pancreatic Cancer Smaglo BG et al. J Clin Oncol 2020. ASCO 2020 Presentation. * Combination therapy demonstrates responses beyond historical survival points (orange & blue lines). Patient 1 Patient 3 Pre-infusion Pre
Slide 20: Corporate & Financial Highlights
Corporate & Financial Highlights Demonstrated clinical response in hematological malignancies and solid tumors Favorable safety profile in clinical trials to date 3 FDA-approved INDs Awarded over $17 million non-dilutive funding through grants Cash & Cash Equivalents of $17.5 million(1) Current cash
Slide 21: Thank You
THANK YOU 21
Marker Therapeutics — Investor Presentation (January 2024) on 6ix